Aurora Spine Corporation (ASAPF)
| Market Cap | 13.34M -24.2% |
| Revenue (ttm) | 18.39M +2.3% |
| Net Income | -584.30K |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,696 |
| Open | 0.1500 |
| Previous Close | n/a |
| Day's Range | 0.1500 - 0.1600 |
| 52-Week Range | 0.1400 - 0.2364 |
| Beta | -0.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Aurora Spine
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTR, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases. It also provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone lumbar fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic pro... [Read more]
Financial Performance
In 2025, Aurora Spine's revenue was $18.37 million, an increase of 4.58% compared to the previous year's $17.56 million. Losses were -$731,120, -27.08% less than in 2024.
Financial StatementsNews
Aurora Spine and CornerLoc Announce Strategic Commercial Alliance to Expand Minimally Invasive Spine and SI Joint Solutions Nationwide
Carlsbad, California and Tulsa, Oklahoma--(Newsfile Corp. - July 16, 2026) - Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groun...
Aurora Spine Transcript: Lytham Partners Spring 2026 Investor Conference
Proprietary spine products simplify procedures, expand patient access, and drive revenue growth, with ZIP and SiLO lines leading innovation. DEXA technology addresses bone density needs, while a new biologics division and upcoming product launches support a comprehensive portfolio.
Aurora Spine Slides: FY 2026
Aurora Spine has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 28, 2026.
Aurora Spine Earnings Call Transcript: Q1 2026
Q1 2026 saw modest revenue growth and a significant margin improvement, driven by proprietary product sales and a strengthened sales team. New product launches and expanded regional coverage are expected to accelerate growth in the second half of the year.
Aurora Spine Registration statement: Q1 2026
Aurora Spine filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Aurora Spine Registration statement: Q1 2026
Aurora Spine filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Aurora Spine Earnings release: Q1 2026
Aurora Spine released its Q1 2026 earnings on May 28, 2026, summarizing the period's financial results.
Aurora Spine Corporation Announces First Quarter FY26 Financial Results
- Company to host conference call Today, May 28th at 10am ET/7am PT – - Company to host conference call Today, May 28th at 10am ET/7am PT –
Aurora Spine Corporation Schedules Release of First Quarter Fiscal 2026 Financial Results
- Company to Participate in the Lytham Partners Spring 2026 Investor Conference - - Company to Participate in the Lytham Partners Spring 2026 Investor Conference -
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology® Bone Density-Matched Implants
CARLSBAD, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices ...
Aurora Spine Earnings Call Transcript: Q4 2025
Record annual and Q4 revenues driven by ZIP, SiLO, and DEXA-L launches, with gross margin improvement and narrowed net loss. Expanded sales force and new product launches position the company for continued growth and cash flow positivity in 2026.
Aurora Spine Registration statement: Q4 2025
Aurora Spine filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Aurora Spine Registration statement: Q4 2025
Aurora Spine filed a registration statement on April 30, 2026, providing details about a securities offering with the SEC.
Aurora Spine Earnings release: Q4 2025
Aurora Spine released its Q4 2025 earnings on April 30, 2026, summarizing the period's financial results.
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
– Q4 revenue surpasses $5 million threshold – –Company to host conference call today, April 30th at 11am ET/8am PT –
Aurora Spine Corporation Schedules Release of Fourth Quarter and Fiscal 2025 Financial Results
CARLSBAD, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical device...
Aurora Spine Corporation to Participate in the 38th Annual ROTH Conference
CARLSBAD, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical device...
AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Aurora Spine Slides: Investor presentation
Aurora Spine has posted slides in relation to its latest quarterly earnings report, which was published on February 5, 2026.
Aurora Spine Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Significant product launches and portfolio expansion are set for 2026, including new cervical and lumbar implants, biologics, and SI joint solutions. Operational improvements, a growing sales team, and strong clinical research underpin a goal of surpassing $20 million in revenue.
Aurora Spine Announces Issuance of Two U.S. Patents
CARLSBAD, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in minimally invasive spine and interventional pain solu...
Aurora Spine Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined 7.1% year-over-year to $4.43M due to a product transition, but gross margin improved to 60.9%. Proprietary launches like Hydra ARO and Dexa L drove record October sales, and the company expects continued growth as adoption expands.
Aurora Spine Earnings release: Q3 2025
Aurora Spine released its Q3 2025 earnings on November 18, 2025, summarizing the period's financial results.
Aurora Spine Registration statement: Q3 2025
Aurora Spine filed a registration statement on November 18, 2025, providing details about a securities offering with the SEC.
Aurora Spine Registration statement: Q3 2025
Aurora Spine filed a registration statement on November 18, 2025, providing details about a securities offering with the SEC.